

1/24




Figure 1

2/24

T05290" 65688860




Figure 2




Figure 2 (ii)

4/24




Figure 2 (ii)

5/24

T05290"65688860




Figure 2 (iii)

6/24

FO5290" 65688860




Figure 2 (iv)

7/24




Figure 3a





Figure 3b


0988959-062501




Flow diagram for the antibody array procedure

Figure 4


CEM CELL ARRAY: T-cell ALL
Nomarski images




CD3 antibody dot binding a low number of CD3+ cells.




The distinct boundary of a CD4 antibody dot binding CD4+ cells.




CD8 antibody dot binding a low number of CD8+ cells.



CD14 antibody dot is negative.




CD19 antibody dot is negative.




CD56 antibody dot is negative.

mag. x 20


RAJI CELL ARRAY: B-cell Burkitt's Lymphoma **Nomarski images**




CD3 antibody dot is negative.




CD4 antibody dot is negative.




CD8 antibody dot is negative.



CD14 antibody dot is negative.



CD19 antibody dot binding
 CD19+ cells.




CD56 antibody dot is negative.

mag. x 20

Figure 5b

0988959 062501



CCRF-CEM cells bound to a CD4 antibody dot and labelled with Alexa-488nm conjugated CD45 antibody.

Figure 6

SUBSTITUTE SHEET
(RULE 26) RO/AU

mIgG1	2	3	4	5	7
8	9	10	11b	11c	13
14	15	16	19	20	21
22	23	24	25	33	34
36	37	38	41	42a	44
44 v3-10	44 v6	45	45 RA	45 RO	52
56	57	60	61	71	79a
95	103	117	122	154	GPA
HLA	KOR	FMC7	mIgG2a	mIg2b	mIgM

Figure 7a
SUBSTITUTE SHEET
(RULE 26) RO/AU

105290" 65688860

0988959.062501




Figure 7b

0988959 062501
T05290" 65688860




Figure 7c

00888959-062504




Figure 7d

SUBSTITUTE SHEET
(RULE 26) RO/AU

mIgG1	2	3	4	5	7
8	9	10	11b	11c	13
14	15	16	19	20	21
22	23	24	25	33	34
36	37	38	41	42a	44
44 v3-10	44 v6	45	45 RA	45 RO	52
56	57	60	61	64	71
79a	79b	80	95	103	117
122	134	138	154	Kappa	Lambda
GPA	HLA	KOR	FMC7	Anti-Ig	IgG2a

Figure 8a

SUBSTITUTE SHEET
(RULE 26) RO/AU

T05290" 65688860

00888959 062501




Figure 8b

005290" 65688860




Figure 8c

SUBSTITUTE SHEET
(RULE 26) RO/AU

0088959-06501




Figure 8d

09888959 062501




Figure 8e

SUBSTITUTE SHEET
(RULE 26) RO/AU

0988959 062501





Figure 8f

SUBSTITUTE SHEET
(RULE 26) RO/AU

005290" 65688860



B Cell Lymphoma (KR)

Figure 8g

SUBSTITUTE SHEET
(RULE 26) RO/AU




Figure 9

24/24




Figure 10